Related Experiment Video
Updated: Dec 30, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
829
Mobile Application Interventions and Weight Loss in Type 2 Diabetes: A Meta-Analysis
Xue Cai1, Shanhu Qiu2, Dan Luo1
1School of Nursing, Peking University, Beijing, China.
Obesity (Silver Spring, Md.)
|January 23, 2020
Summary
Mobile apps effectively promote weight loss in type 2 diabetes patients, significantly reducing body weight and waist circumference. These digital health interventions are recommended for managing weight in this population.
Area of Science:
- Metabolic Health
- Digital Health Interventions
- Clinical Research
Background:
- Type 2 diabetes management often requires weight loss for improved glycemic control and reduced cardiovascular risk.
- Traditional weight loss interventions face challenges in long-term adherence and accessibility.
- Mobile applications offer a scalable platform for delivering behavioral interventions.
Purpose of the Study:
- To systematically evaluate the efficacy of mobile application (app) interventions in promoting weight loss among individuals with type 2 diabetes.
- To quantify the impact of app-based interventions on body weight, body mass index (BMI), and waist circumference.
Main Methods:
- A meta-analysis was conducted, synthesizing data from randomized controlled trials (RCTs) identified through comprehensive electronic database searches.
- Studies focused on mobile app interventions targeting weight loss outcomes in type 2 diabetes patients.
- A random-effects model was employed to calculate pooled mean differences and 95% confidence intervals (CIs).
Main Results:
- Fourteen studies involving 2,129 patients were analyzed.
- Mobile app interventions significantly reduced body weight (mean difference: -0.84 kg; 95% CI: -1.51 to -0.17 kg) and waist circumference (mean difference: -1.35 cm; 95% CI: -2.16 to -0.55 cm).
- No significant reduction in BMI was observed (mean difference: -0.08 kg/m²; 95% CI: -0.41 to 0.25 kg/m²).
Conclusions:
- Mobile application interventions are effective in achieving weight loss and reducing waist circumference in patients with type 2 diabetes.
- The benefits were more pronounced in patients with obesity and when apps were combined with other behavioral strategies.
- App functionalities and intervention duration did not significantly moderate weight loss outcomes.
Related Concept Videos
Carbohydrate Metabolism
13.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.6K
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
538
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
538
Diabetes: Management and Pharmacotherapy
792
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
792
Diabetes Mellitus: Overview and Type I Subtype
4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Insulin: Dosing Regimen and Adverse Effects
605
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
605

